Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
MWN-AI** Summary
Ernexa Therapeutics (Nasdaq: ERNA), a leading innovator in cell therapies for advanced cancer and autoimmune diseases, has been selected as one of only ten global companies to participate in the Japan Entry Acceleration Program (JEAP) by the Japan External Trade Organization (JETRO). This prestigious program is highly competitive, attracting around 70 regenerative medicine companies from 25 countries. Ernexa's selection highlights its unique cell therapy platform and its potential to significantly enhance Japan's renowned regenerative medicine and oncology landscape.
With six of the ten chosen companies focusing on oncology, Ernexa stands out among innovators in one of the most critical therapeutic domains. Sanjeev Luther, the CEO of Ernexa Therapeutics, emphasized Japan's leadership in regenerative medicine and the advantages of the JEAP program, which includes expert-led mentoring and insights on navigating Japan's regulatory, clinical, and commercial environments. This access will enable Ernexa to forge strategic partnerships and explore opportunities to expand its offerings internationally.
Ernexa's pipeline features two lead cell therapy candidates: ERNA-101, aimed at helping the immune system recognize and combat ovarian cancer, and ERNA-201, targeting harmful inflammation associated with autoimmune diseases. With ERNA-101 set to enter first-in-human trials this year, Ernexa is poised to advance its clinical programs significantly within Japan.
The JEAP, part of the J-Bridge initiative, aims to boost international investment and partnerships in the regenerative medicine sector. Ernexa's participation not only reflects its commitment to pioneering therapies but also its dedication to providing hope to patients facing challenging health conditions. For further information, visit www.ernexatx.com.
MWN-AI** Analysis
Ernexa Therapeutics (NASDAQ: ERNA), recently selected for the prestigious Japan Entry Acceleration Program (JEAP), presents a compelling investment opportunity due to its innovative approach in the cell therapy sector, particularly in oncology and autoimmune diseases. With its participation in JEAP, Ernexa gains unprecedented access to Japan's robust regenerative medicine landscape, a move that could significantly enhance its clinical and commercial potential.
The selection out of 70 global contenders reaffirms Ernexa’s status as an industry leader, especially with two promising candidates in its pipeline: ERNA-101, targeting ovarian cancer, and ERNA-201, focused on autoimmune diseases. The imminent initiation of first-in-human trials for ERNA-101 is a critical milestone, as the treatment addresses unmet needs in a high-value therapeutic area. The backing of JETRO not only provides strategic mentorship but also connects Ernexa with potential partnerships in Japan, a country renowned for its supportive regulatory environment and strong R&D capabilities.
Investors should closely monitor the outcomes of Ernexa's trials and its synergy with Japanese firms. Japan's advanced healthcare system presents opportunities for quick market entry and scalability of Ernexa's allogeneic synthetic iMSCs, making the company's offerings attractive globally.
Given the competitive selection process and the increasing urgency for innovative cancer therapies, Ernexa stands out as a high-potential investment. Its commitment to pushing scientific boundaries while enhancing patient outcomes aligns well with the growing demand for personalized medicine. As such, potential investors should consider building positions in Ernexa Therapeutics, recognizing the company’s strategic positioning in a powerful market and its potential for substantial growth in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO).
JEAP drew approximately 70 regenerative medicine companies from 25 countries, underscoring the competitiveness of the selection process. Ernexa was chosen for its differentiated cell therapy platform and its potential to contribute meaningfully to Japan’s globally recognized regenerative medicine and oncology ecosystem. Notably, six of the ten selected companies focus on oncology, placing Ernexa among an elite group recognized for innovation in one of the world’s most critical and high-value therapeutic areas.
“Japan is a world leader in regenerative medicine, supported by a progressive regulatory framework and deep oncology expertise. Participation in JEAP gives us direct access to key stakeholders as we evaluate strategic partnerships, clinical development opportunities and potential pathways to expand our platform internationally. Our ultimate goal is to deliver hope to patients with cancer and autoimmune conditions worldwide,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics.
As a selected participant, Ernexa will receive expert-led mentoring and market-entry guidance focused on Japan’s regulatory, clinical and commercial landscape. The program also provides direct engagement opportunities with leading Japanese research and development organizations, including CDMOs and CROs, to explore potential collaborations across development, manufacturing and clinical execution.
The program will help advance Ernexa’s pipeline in Japan. Ernexa’s pipeline is anchored by two lead cell therapy programs. ERNA-101 is being developed to help the immune system better recognize and attack tumors, addressing the profound unmet need in cancers such as ovarian cancer, where effective long-term treatment options remain limited. The drug candidate is entering first-in-human clinical trials in ovarian cancer this year. ERNA-201 is designed to target harmful inflammation at its source in autoimmune disease, with the goal of restoring balance to an overactive immune system rather than broadly suppressing it. Together, these programs exemplify Ernexa’s commitment to advancing next-generation therapies that not only push scientific boundaries but also offer meaningful new hope to patients facing serious, life-altering conditions.
JEAP is JETRO’s first acceleration program for overseas startups and is part of the Japanese government-backed J-Bridge initiative, which aims to attract international investment and foster strategic collaboration between global innovators and Japanese companies. The program focuses on accelerating business co-creation opportunities within the regenerative medicine sector, including oncology.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com
Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com
FAQ**
How does Eterna Therapeutics Inc. ERNA plan to leverage the mentorship and network gained from the Japan Entry Acceleration Program (JEAP) to enhance its clinical development strategy for ERNA-101 and ERNA-201 in the Japanese market?
What specific regulatory advantages does Eterna Therapeutics Inc. ERNA anticipate encountering in Japan for its cell therapies, particularly with ERNA-101 targeting ovarian cancer?
In what ways does Eterna Therapeutics Inc. ERNA envision its collaboration with Japanese research and development organizations strengthening its position in the competitive oncology landscape?
Given the focus on regenerative medicine in Japan, how does Eterna Therapeutics Inc. ERNA plan to differentiate its allogeneic synthetic iMSCs from existing therapies in terms of scalability and patient outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Eterna Therapeutics Inc. (NASDAQ: ERNA).
NASDAQ: ERNA
ERNA Trading
11.38% G/L:
$0.3201 Last:
2,956,671 Volume:
$0.2825 Open:
